Area of research
Genetics · Hematology
Research interest
Research interests include Medicine, Internal medicine, Myelofibrosis, Polycythemia vera, Oncology, and Essential thrombocythemia.
<scp><i>TP53</i></scp> Mutations in Myeloproliferative Neoplasms: Context‐Dependent Evaluation of Prognostic Relevance
Multihit <scp><i>TP53</i></scp> Mutations in Myeloproliferative Neoplasms and Acute Myeloid Leukemia: Comparative Analysis of Survival and Risk Factors in 142 Informative Cases
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent
Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Single‐agent cladribine as an effective front‐line therapy for adults with Langerhans cell histiocytosis
Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients
Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis
The effect of arterial hypertension on thrombosis in low‐risk polycythemia vera
Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition
A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology
Mutations and prognosis in primary myelofibrosis
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
AKT is a therapeutic target in myeloproliferative neoplasms
A Phase II Randomized Dose-Ranging Study of the JAK2-Selective Inhibitor SAR302503 in Patients with Intermediate-2 or High-Risk Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, or Post-Essential Thrombocythemia (ET) MF.
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: Proceedings from the 6th international post‐ASH symposium